Patrick Hutchison Net Worth

Patrick Hutchison biography

Patrick Hutchison serves as Chief Financial Officer of the Company. Previously, he served as the Chief Financial Officer of SwanBio Therapeutics (“SwanBio”), a private gene therapy biotech company, on a part-time basis from April 2019 through December 2019. Before SwanBio, from April 2017 to August 2018, Mr. Hutchison served as the Chief Financial Officer of Innocoll, Inc., a private biotech company. Prior to that, Mr. Hutchison served as the Chief Financial Officer of TetraLogic, a public biotech company, from April 2016 to December 2016 and as TetraLogic’s Vice President – Finance from January 2014 to April 2016. From 2012 to 2013, Mr. Hutchison was Teleflex, Inc.’s Vice President – Corporate Controller and Chief Accounting Officer. Before his time at Teleflex, Inc., from 2001 to 2012, Mr. Hutchison was Vice President – Group Controller of Cephalon, Inc., an international biopharmaceutical company. Mr. Hutchison received his B.S. degree in Accounting from the Wharton School of the University of Pennsylvania (“UPenn”); he also earned a B.A. degree in Psychology from UPenn.

How old is Patrick Hutchison?

Patrick Hutchison is 62, he's been the Chief Financial Officer of Biospecifics Technologies since 2020. There are 4 older and 4 younger executives at Biospecifics Technologies. The oldest executive at Biospecifics Technologies Corp. is Toby Wegman, 85, who is the Director.

What's Patrick Hutchison's mailing address?

Patrick's mailing address filed with the SEC is C/O BIOSPECIFICS TECHNOLOGIES CORP., 2 RIGHTER PKWY, DE CORP CENTER II, WILMINGTON, DE, 19803.

Insiders trading at Biospecifics Technologies

Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo y Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.

What does Biospecifics Technologies do?

Biospecifics Technologies executives and stock owners

Biospecifics Technologies executives and other stock owners filed with the SEC include:

• Jennifer Chao,
  Independent Chairman of the Board
• Michael Schamroth,
  Independent Director
• Paul Gitman,
  Independent Director
• Mark Wegman,
  Director
• Toby Wegman,
  Director
• Sarah McCabe,
  Stern Investor Relations
• Michael Sherman,
  Independent Director
• Corey Fishman,
  Independent Director
• Alex Monteith,
  Senior Vice President and Chief Business Officer
• Patrick Hutchison,
  Chief Financial Officer
• Joseph Truitt,
  Chief Executive Officer, Director
• Jeffrey Kenneth Vogel,
  
• Jyrki Mattila,
  Director
• Thomas Wegman,
  President
• Of Edwin H. Wegman Estate,
  10% owner
• Patrick M Caldwell,
  Principal Financial Officer
• Partners Lp Bio,
  10% owner
• Albert Horcher,
  
• Lawrence Dobroff,
  CFO
• Max Link,
  Director
• Henry Morgan,
  Director
• George M Gould,
  Director
• Matthew Geller,
  Director
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• Capital Management, Llcaldr...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, Llcra C...,
  
• J Kevin Buchi,
  Chief Executive Officer
• International Plc Endo,
  10% owner